NF-κB/IκB - HDAC4

CUDC-101 is a novel compound which inhibits multiple targets, which is designed to inhibit HDAC, EGFR and Her2.

JNJ-26481585 (Quisinostat) is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC(50), 0.16 nmol/L).

Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.